PANoptosis is a prominent feature of desmoplakin cardiomyopathy

Abstract

Introduction: Arrhythmogenic cardiomyopathy (ACM) is hereditary cardiomyopathy caused by pathogenic variants (mutations) in genes encoding the intercalated disc (ID), particularly desmosome proteins. ACM caused by mutations in the DSP gene encoding desmoplakin (DSP) is characterized by the prominence of cell death, myocardial fibrosis, and inflammation, and is referred to as desmoplakin cardiomyopathy.

Aim: The aim of this article was to gain insight into the pathogenesis of DSP cardiomyopathy.

Methods and Results: The Dsp gene was exclusively deleted in cardiac myocytes using tamoxifen-inducible MerCreMer (Myh6-Mcm^Tam) and floxed Dsp (Dsp^F/F) mice (Myh6-Mcm^Tam:Dsp^F/F). Recombination was induced upon subcutaneous injection of tamoxifen (30 mg/kg/d) for 5 days starting post-natal day 14. Survival was analyzed by Kaplan-Meier plots, cardiac function by echocardiography, arrhythmias by rhythm monitoring, and gene expression by RNA-Seq, immunoblotting, and immunofluorescence techniques. Cell death was analyzed by the TUNEL assay and the expression levels of specific markers were by RT-PCR and immunoblotting. Myocardial fibrosis was assessed by picrosirius red staining of the myocardial sections, RT-PCR, and immunoblotting. The Myh6-Mcm^Tam:Dsp^F/F mice showed extensive molecular remodeling of the IDs and the differential expression of ~10,000 genes, which predicted activation of KDM5A, IRFs, and NFκB and suppression of PPARGC1A and RB1, among others in the DSP-deficient myocytes. Gene set enrichment analysis predicted activation of the TNFα/NFκB pathway, inflammation, cell death programs, and fibrosis. Analysis of cell death markers indicated PANoptosis, comprised of apoptosis (increased CASP3, CASP8, BAD and reduced BCL2), necroptosis (increased RIPK1, RIPK3, and MLKL), and pyroptosis (increased GSDMD and ASC or PYCARD) in the DSP-deficient myocytes. Transcript levels of the pro-inflammatory and pro-fibrotic genes were increased and myocardial fibrosis comprised ~25% of the myocardium in the DSP-deficient hearts. The Myh6-Mcm^Tam:Dsp^F/F mice showed severe cardiac systolic dysfunction and ventricular arrhythmias, and died prematurely with a median survival rate of ~2 months.

Conclusion: The findings identify PANoptosis as a prominent phenotypic feature of DSP cardiomyopathy and set the stage for delineating the specific molecular mechanisms involved in its pathogenesis. The model also provides the opportunity to test the effects of pharmacological and genetic interventions on myocardial fibrosis and cell death.

One sentence summary: Post-natal homozygous deletion of the Dsp gene leads to fulminant PANoptosis and severe myocardial fibrosis, cardiac dysfunction, arrhythmias, and premature death in mice.

Keywords

Desmoplakin cardiomyopathy / PANoptosis / apoptosis / necroptosis / pyroptosis / inflammation / fibrosis

References

[1] Corrado D,Judge DP.Arrhythmogenic cardiomyopathy.Circ Res2017;121:784-802

[2] Marcus FI,Guiraudon G.Right ventricular dysplasia: a report of 24 adult cases.Circulation1982;65:384-98

[3] Basso C,Corrado D,Nava A.Arrhythmogenic right ventricular cardiomyopathy. dysplasia, dystrophy, or myocarditis?.Circulation1996;94:983-91

[4] Sen-Chowdhry S,Prasad SK.Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity.J Am Coll Cardiol2008;52:2175-87

[5] Corrado D,Calkins H.Arrhythmogenic right ventricular cardiomyopathy.N Engl J Med2017;376:61-72

[6] Mayosi BM,Shaboodien G.Identification of cadherin 2 (CDH2) mutations in arrhythmogenic right ventricular cardiomyopathy.Circ Cardiovasc Genet2017;10:e001605

[7] van Hengel J,Bauce B.Mutations in the area composita protein αT-catenin are associated with arrhythmogenic right ventricular cardiomyopathy.Eur Heart J2013;34:201-10

[8] Ortiz-Genga MF,Dal Ferro M.Truncating FLNC mutations are associated with high-risk dilated and arrhythmogenic cardiomyopathies.J Am Coll Cardiol2016;68:2440-51

[9] van der Zwaag PA,Asimaki A.Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy.Eur J Heart Fail2012;14:1199-207 PMCID:PMC3475434

[10] Parikh VN,Reuter C.Regional variation in RBM20 causes a highly penetrant arrhythmogenic cardiomyopathy.Circ Heart Fail2019;12:e005371 PMCID:PMC6422044

[11] Quarta G,Ashworth M.Mutations in the lamin A/C gene mimic arrhythmogenic right ventricular cardiomyopathy.Eur Heart J2012;33:1128-36

[12] Merner ND,Haywood AF.Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused by a missense mutation in the TMEM43 gene.Am J Hum Genet2008;82:809-21 PMCID:PMC2427209

[13] Alcalai R,Rosenheck S,Chajek-shaul T.A recessive mutation in desmoplakin causes arrhythmogenic right ventricular dysplasia, skin disorder, and woolly hair.J Am College Cardiol2003;42:319-27

[14] Norgett EE,Carvajal-Huerta L.Recessive mutation in desmoplakin disrupts desmoplakin-intermediate filament interactions and causes dilated cardiomyopathy, woolly hair and keratoderma.Hum Mol Genet2000;9:2761-6

[15] Mckoy G,Crosby A.Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease).Lancet2000;355:2119-24

[16] Smith ED,Papoutsidakis N.Desmoplakin cardiomyopathy, a fibrotic and inflammatory form of cardiomyopathy distinct from typical dilated or arrhythmogenic right ventricular cardiomyopathy.Circulation2020;141:1872-84

[17] Castelletti S,Syrris P.Desmoplakin missense and non-missense mutations in arrhythmogenic right ventricular cardiomyopathy: genotype-phenotype correlation.Int J Cardiol2017;249:268-73

[18] López-Ayala JM,Sánchez Muñoz JJ.Desmoplakin truncations and arrhythmogenic left ventricular cardiomyopathy: characterizing a phenotype.Europace2014;16:1838-46

[19] Norman M,Mogensen J.Novel mutation in desmoplakin causes arrhythmogenic left ventricular cardiomyopathy.Circulation2005;112:636-42

[20] Wang W,Tichnell C.Clinical characteristics and risk stratification of desmoplakin cardiomyopathy.Europace2022;24:268-77 PMCID:PMC8824516

[21] Gallicano GI,Bauer C.Desmoplakin is required early in development for assembly of desmosomes and cytoskeletal linkage.J Cell Biol1998;143:2009-22 PMCID:PMC2175222

[22] Garcia-Gras E,Giocondo MJ.Suppression of canonical Wnt/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy.J Clin Invest2006;116:2012-21 PMCID:PMC1483165

[23] Rouhi L,Cheedipudi SM.The EP300/TP53 pathway, a suppressor of the Hippo and canonical WNT pathways, is activated in human hearts with arrhythmogenic cardiomyopathy in the absence of overt heart failure.Cardiovasc Res2022;118:1466-78 PMCID:PMC9074970

[24] Chen SN,Lombardi R,Willerson JT.The hippo pathway is activated and is a causal mechanism for adipogenesis in arrhythmogenic cardiomyopathy.Circ Res2014;114:454-68 PMCID:PMC3946717

[25] Liang Y,Pellman J.Desmosomal COP9 regulates proteome degradation in arrhythmogenic right ventricular dysplasia/cardiomyopathy.J Clin Invest2021;131:137689 PMCID:PMC8159691

[26] Vleminckx K,Hecht A.The C-terminal transactivation domain of β-catenin is necessary and sufficient for signaling by the LEF-1/β-catenin complex in Xenopus laevis.Mech Dev1999;81:65-74

[27] Harada N,Ishikawa T.Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene.EMBO J1999;18:5931-42 PMCID:PMC1171659

[28] Rouhi L,Cheedipudi SM.Effects of tamoxifen inducible MerCreMer on gene expression in cardiac myocytes in mice.J Cardiovasc Aging2022;2:8

[29] Cheedipudi SM,Fan S.Exercise restores dysregulated gene expression in a mouse model of arrhythmogenic cardiomyopathy.Cardiovasc Res2020;116:1199-213 PMCID:PMC7177479

[30] Auguste G,Lombardi R,Willerson JT.Suppression of Activated FOXO transcription factors in the heart prolongs survival in a mouse model of laminopathies.Circ Res2018;122:678-92 PMCID:PMC5834384

[31] Devereux RB,Lutas EM.Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings.Am J Cardiol1986;57:450-8

[32] Pfaffenberger S,Graf A.Size matters! impact of age, sex, height, and weight on the normal heart size.Circ Cardiovasc Imaging2013;6:1073-9

[33] Auguste G,Matkovich SJ.BET bromodomain inhibition attenuates cardiac phenotype in myocyte-specific lamin A/C-deficient mice.J Clin Invest2020;130:4740-58 PMCID:PMC7456228

[34] Rouhi L,Chen SN.Haploinsufficiency of Tmem43 in cardiac myocytes activates the DNA damage response pathway leading to a late-onset senescence-associated pro-fibrotic cardiomyopathy.Cardiovasc Res2021;117:2377-94 PMCID:PMC8861264

[35] Olcum M,Rouhi L.The WNT/β-catenin pathway regulates expression of the genes involved in cell cycle progression and mitochondrial oxidative phosphorylation in the postmitotic cardiac myocytes.J Cardiovasc Aging2022;2:15 PMCID:PMC8874274

[36] Bergmann O.Isolation of cardiomyocyte nuclei from post-mortem tissue.J Vis Exp2012:4205 PMCID:PMC3476409

[37] Bergmann O,Alkass K,Bernard S.Identification of cardiomyocyte nuclei and assessment of ploidy for the analysis of cell turnover.Exp Cell Res2011;317:188-94

[38] Chen SN,Karmouch J.DNA Damage response/TP53 pathway is activated and contributes to the pathogenesis of dilated cardiomyopathy associated with LMNA (Lamin A/C) mutations.Circ Res2019;124:856-73 PMCID:PMC6460911

[39] Karmouch J,Miyake CY.Distinct cellular basis for early cardiac arrhythmias, the cardinal manifestation of arrhythmogenic cardiomyopathy, and the skin phenotype of cardiocutaneous syndromes.Circ Res2017;121:1346-59 PMCID:PMC5722680

[40] Wingett SW.FastQ screen: a tool for multi-genome mapping and quality control.F1000Res2018;7:1338 PMCID:PMC6124377

[41] Love MI,Anders S.Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.Genome Biol2014;15:550 PMCID:PMC4302049

[42] Zheng M.The regulation of the ZBP1-NLRP3 inflammasome and its implications in pyroptosis, apoptosis, and necroptosis (PANoptosis).Immunol Rev2020;297:26-38 PMCID:PMC7811275

[43] Asimaki A,Ward D,Saffitz JE.Unique epidermolytic bullous dermatosis with associated lethal cardiomyopathy related to novel desmoplakin mutations.J Cutan Pathol2009;36:553-9

[44] Antonov NK,Rohena LO.Early-onset heart failure, alopecia, and cutaneous abnormalities associated with a novel compound heterozygous mutation in desmoplakin.Pediatr Dermatol2015;32:102-8

[45] Hall CL,Sabater-Molina M.RNA sequencing-based transcriptome profiling of cardiac tissue implicates novel putative disease mechanisms in FLNC-associated arrhythmogenic cardiomyopathy.Int J Cardiol2020;302:124-30 PMCID:PMC6940594

[46] Walsh JG,Sheridan C,Gerner C.Executioner caspase-3 and caspase-7 are functionally distinct proteases.Proc Natl Acad Sci USA2008;105:12815-9 PMCID:PMC2529079

[47] Rozan LM.Identification and characterization of proteins interacting with Traf4, an enigmatic p53 target.Cancer Biol Ther2006;5:1228-35

[48] Li J,Yang H.Spatiotemporal profile of postsynaptic interactomes integrates components of complex brain disorders.Nat Neurosci2017;20:1150-61 PMCID:PMC5645082

[49] Jalving M,Koornstra JJ.Regulation of TRAIL receptor expression by β-catenin in colorectal tumours.Carcinogenesis2014;35:1092-9

[50] Asatryan B,Landstrom AP.Inflammation and immune response in arrhythmogenic cardiomyopathy: state-of-the-art review.Circulation2021;144:1646-55 PMCID:PMC9034711

[51] Teekakirikul P,Toka O.Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β.J Clin Invest2010;120:3520-9 PMCID:PMC2947222

[52] Koitabashi N,Zaiman AL.Avoidance of transient cardiomyopathy in cardiomyocyte-targeted tamoxifen-induced MerCreMer gene deletion models.Circ Res2009;105:12-5 PMCID:PMC2747596

[53] Hall ME,Hall JE.Systolic dysfunction in cardiac-specific ligand-inducible MerCreMer transgenic mice.Am J Physiol Heart Circ Physiol2011;301:H253-60 PMCID:PMC3129917

[54] Heinen A,Flögel U.4-hydroxytamoxifen does not deteriorate cardiac function in cardiomyocyte-specific MerCreMer transgenic mice.Basic Res Cardiol2021;116:8